Veracyte, Inc. (NASDAQ:VCYT – Get Rating) Director Jens Holstein sold 8,720 shares of Veracyte stock in a transaction on Tuesday, June 14th. The shares were sold at an average price of $16.27, for a total transaction of $141,874.40. Following the completion of the sale, the director now owns 2,000 shares in the company, valued at $32,540. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Veracyte stock opened at $16.97 on Friday. Veracyte, Inc. has a 1 year low of $14.85 and a 1 year high of $54.13. The firm has a 50-day moving average of $19.75 and a two-hundred day moving average of $27.56.
Veracyte (NASDAQ:VCYT – Get Rating) last released its quarterly earnings data on Tuesday, May 3rd. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.03. The company had revenue of $67.78 million during the quarter, compared to analysts’ expectations of $61.98 million. Veracyte had a negative net margin of 19.22% and a negative return on equity of 4.09%. During the same period in the previous year, the company earned ($0.11) EPS. As a group, research analysts expect that Veracyte, Inc. will post -0.86 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in the company. ARK Investment Management LLC lifted its position in shares of Veracyte by 6.5% in the 1st quarter. ARK Investment Management LLC now owns 8,756,024 shares of the biotechnology company’s stock worth $241,404,000 after purchasing an additional 533,743 shares during the period. Wellington Management Group LLP lifted its position in shares of Veracyte by 84.3% in the 3rd quarter. Wellington Management Group LLP now owns 5,069,351 shares of the biotechnology company’s stock worth $235,471,000 after purchasing an additional 2,319,050 shares during the period. Invesco Ltd. lifted its position in shares of Veracyte by 0.4% in the 1st quarter. Invesco Ltd. now owns 4,131,597 shares of the biotechnology company’s stock worth $113,908,000 after purchasing an additional 17,566 shares during the period. State Street Corp raised its stake in shares of Veracyte by 45.5% during the 1st quarter. State Street Corp now owns 3,945,870 shares of the biotechnology company’s stock worth $108,788,000 after acquiring an additional 1,234,244 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of Veracyte by 5.6% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,121,103 shares of the biotechnology company’s stock worth $128,589,000 after acquiring an additional 164,724 shares in the last quarter.
Veracyte Company Profile (Get Rating)
Veracyte, Inc operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis.
- Get a free copy of the StockNews.com research report on Veracyte (VCYT)
- Vuzix Stock Stays Optimistic
- Palo Alto Networks: Pioneering AI in Cybersecurity
- The Analysts Upgrade… Retail Stocks?
- Dividend Stocks and Your Roth IRA
- The Q2 Earnings Season Could Be A Bloodbath
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.